Pharsight

Drug Patents owned by Boehringer Ingelheim

1. List of Atrovent Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(6 years from now)

Do you want to check out ATROVENT HFA patents from before 2022?

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ATROVENT HFA family patents

2

European Union

1

Germany

1

Canada

1

Denmark

1

Hungary

1

Spain

1

Poland

1

Japan

1

United States

2. List of Combivent Respimat drug patents

COMBIVENT RESPIMAT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 2 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 11 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Do you want to check out COMBIVENT RESPIMAT patents from before 2022?

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

COMBIVENT RESPIMAT family patents

12

European Union

9

Germany

9

United States

6

Japan

5

Canada

5

Spain

4

Australia

4

Denmark

4

Austria

3

Colombia

3

Korea, Republic of

3

Cyprus

3

Portugal

3

Poland

3

Slovenia

3

Mexico

3

Brazil

3

China

3

South Africa

2

Ecuador

EA

2

EA

2

Croatia

2

New Zealand

2

Uruguay

2

Peru

2

Ukraine

2

Norway

2

Hong Kong

2

Argentina

2

Taiwan

1

Israel

1

Egypt

YU

1

Yugoslavia

1

Malaysia

1

ME

1

Russia

1

RS

3. List of Gilotrif drug patents

GILOTRIF's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(2 years from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jul, 2026

(3 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(3 years from now)

US9539258

(Pediatric)

 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(3 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(6 years from now)

US8426586

(Pediatric)

 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(6 years from now)

US8545884

(Pediatric)

 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(7 years from now)

US10004743

(Pediatric)

 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(7 years from now)

Do you want to check out GILOTRIF patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M (M) Apr 7, 2025
Pediatric Exclusivity (PED) Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage

GILOTRIF family patents

15

European Union

13

United States

6

Canada

6

Japan

4

Croatia

4

Denmark

4

Spain

4

Portugal

4

Poland

4

Slovenia

3

Australia

3

Israel

3

Korea, Republic of

3

New Zealand

3

Uruguay

3

Peru

3

Malaysia

3

Cyprus

3

Ukraine

3

Mexico

3

RS

3

Brazil

3

China

3

Hungary

3

Taiwan

2

Ecuador

EA

2

EA

2

ME

2

Norway

2

Hong Kong

2

Argentina

2

South Africa

1

Colombia

YU

1

Yugoslavia

1

Tunisia

1

Chile

1

Singapore

1

Morocco

1

Germany

1

Lithuania

4. List of Glyxambi drug patents

GLYXAMBI's oppositions filed in EPO
GLYXAMBI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 10 months from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(3 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Do you want to check out GLYXAMBI patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's patent expiration?
More Information on Dosage

GLYXAMBI family patents

52

United States

47

European Union

36

Japan

33

China

25

Korea, Republic of

18

New Zealand

17

Hong Kong

EA

15

EA

15

Argentina

14

Canada

14

Taiwan

13

Spain

13

Peru

12

Poland

12

Norway

12

Mexico

12

Germany

11

Australia

11

Denmark

10

Croatia

10

Malaysia

10

Portugal

10

Brazil

9

Cyprus

9

Slovenia

9

RS

8

Israel

8

Uruguay

8

Chile

8

ME

8

Ukraine

7

South Africa

7

Hungary

6

Ecuador

6

Singapore

5

Austria

3

Luxembourg

3

Philippines

3

Lithuania

2

India

2

Turkey

1

Colombia

1

Egypt

1

Netherlands

YU

1

Yugoslavia

1

Tunisia

1

Saudi Arabia

1

Morocco

1

Belgium

5. List of Jardiance drug patents

JARDIANCE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(3 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Do you want to check out JARDIANCE patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Aug 18, 2024
M (M) Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1....

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's patent expiration?
More Information on Dosage

JARDIANCE family patents

33

United States

24

European Union

14

China

13

Japan

9

Canada

8

Israel

8

Korea, Republic of

8

Hong Kong

8

Argentina

6

Australia

6

Spain

6

Peru

EA

5

EA

5

Croatia

5

New Zealand

5

Denmark

5

Portugal

5

Poland

5

Norway

5

Germany

5

Mexico

5

RS

5

Taiwan

4

Uruguay

4

Chile

4

Cyprus

4

Slovenia

4

Hungary

4

Lithuania

3

Malaysia

3

Austria

3

ME

3

Ukraine

3

Philippines

3

South Africa

3

Brazil

2

Ecuador

1

Colombia

1

Luxembourg

1

Netherlands

1

Tunisia

1

Singapore

1

Morocco

1

Finland

1

Turkey

6. List of Jentadueto drug patents

JENTADUETO's oppositions filed in EPO
JENTADUETO Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(5 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(5 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

Do you want to check out JENTADUETO patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea; Method of treating type 2 diabetes mellitus by adm...

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's patent expiration?
More Information on Dosage

JENTADUETO family patents

37

United States

26

European Union

25

China

24

Japan

18

Korea, Republic of

16

New Zealand

EA

12

EA

10

Taiwan

9

Hong Kong

9

Mexico

8

Australia

8

Canada

7

Peru

7

Argentina

7

Brazil

6

Spain

6

Poland

6

Norway

6

Germany

5

Denmark

5

Malaysia

5

Chile

5

Ukraine

4

Ecuador

4

Croatia

4

Uruguay

4

Singapore

4

Portugal

4

South Africa

3

ME

3

Cyprus

3

Slovenia

3

RS

3

Hungary

2

Luxembourg

2

India

2

Israel

2

Philippines

2

Turkey

1

Colombia

1

Egypt

YU

1

Yugoslavia

1

Tunisia

1

Saudi Arabia

1

Austria

1

Morocco

1

Belgium

7. List of Jentadueto Xr drug patents

JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(5 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(6 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(9 years from now)

Do you want to check out JENTADUETO XR patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's patent expiration?
More Information on Dosage

JENTADUETO XR family patents

40

United States

25

China

25

European Union

23

Japan

18

Korea, Republic of

14

New Zealand

EA

12

EA

10

Hong Kong

10

Taiwan

9

Mexico

8

Australia

8

Canada

7

Peru

7

Argentina

6

Spain

6

Poland

6

Norway

6

Germany

6

Brazil

5

Denmark

5

Malaysia

5

Chile

5

Singapore

5

Ukraine

4

Ecuador

4

Croatia

4

Uruguay

4

Portugal

4

South Africa

3

India

3

ME

3

Cyprus

3

Philippines

3

Slovenia

3

RS

3

Hungary

2

Luxembourg

2

Israel

2

Turkey

1

Colombia

1

Egypt

YU

1

Yugoslavia

1

Tunisia

1

Saudi Arabia

1

Austria

1

Morocco

1

Belgium

8. List of Micardis drug patents

MICARDIS's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Oct, 2022

(7 months ago)

Do you want to check out MICARDIS patents from before 2022?

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 10 November, 1998

Treatment: Treatment or prevention of stroke

Dosage: TABLET;ORAL

How can I launch a generic of MICARDIS before it's patent expiration?
More Information on Dosage

MICARDIS family patents

10

United States

4

European Union

3

Korea, Republic of

3

United Kingdom

2

Germany

2

Canada

2

Denmark

2

Portugal

2

Hungary

2

Spain

2

Uruguay

2

Poland

2

Japan

2

Austria

AP

1

AP

1

China

1

Australia

1

Norway

9. List of Mirapex Er drug patents

MIRAPEX ER's oppositions filed in EPO
MIRAPEX ER Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
Apr, 2028

(4 years from now)

US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form
Sep, 2029

(6 years from now)

Do you want to check out MIRAPEX ER patents from before 2022?

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 February, 2010

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MIRAPEX ER before it's patent expiration?
More Information on Dosage

MIRAPEX ER family patents

25

United States

16

European Union

10

Japan

9

China

8

Australia

EA

7

EA

7

Korea, Republic of

7

Canada

7

New Zealand

6

Mexico

6

Brazil

6

South Africa

6

Taiwan

5

Denmark

5

Spain

5

Cyprus

5

Portugal

5

Poland

5

Norway

5

Hong Kong

5

Slovenia

5

Argentina

4

Ecuador

4

Croatia

4

Austria

4

ME

4

Ukraine

4

Germany

3

Israel

3

Malaysia

3

RS

2

Panama

2

Iceland

AP

2

AP

OA

2

OA

2

Tunisia

2

Uruguay

2

Peru

2

Costa Rica

2

Singapore

2

Morocco

2

Georgia

2

Cuba

YU

1

Yugoslavia

1

Russia

10. List of Ofev drug patents

OFEV's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(8 months from now)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jan, 2026

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(6 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(6 years from now)

Do you want to check out OFEV patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 6, 2026
New Indication (I) Mar 9, 2023

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's patent expiration?
More Information on Dosage

OFEV family patents

20

United States

15

European Union

6

Japan

6

Norway

5

Australia

5

Korea, Republic of

5

Denmark

5

Spain

5

Portugal

5

Poland

5

Slovenia

5

Argentina

5

China

EA

4

EA

4

Croatia

4

Canada

4

New Zealand

4

Peru

4

Cyprus

4

Ukraine

4

Mexico

4

Brazil

4

South Africa

4

Hungary

4

Taiwan

4

Lithuania

3

Ecuador

3

Israel

3

Uruguay

3

Malaysia

3

RS

2

Colombia

2

Tunisia

2

Chile

2

ME

2

Morocco

2

Hong Kong

1

Luxembourg

1

Egypt

YU

1

Yugoslavia

1

Saudi Arabia

1

Austria

1

Singapore

1

Germany

1

Belgium

1

Turkey

11. List of Pradaxa drug patents

PRADAXA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380

(Pediatric)

 BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Jun, 2022

(11 months ago)

US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Jun, 2023

(10 days from now)

US9925174

(Pediatric)

 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Dec, 2023

(6 months from now)

US7932273

(Pediatric)

 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Mar, 2026

(2 years from now)

US7866474 BOEHRINGER INGELHEIM Film container
Aug, 2027

(4 years from now)

US7866474

(Pediatric)

 BOEHRINGER INGELHEIM Film container
Mar, 2028

(4 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(7 years from now)

US9034822

(Pediatric)

 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(8 years from now)

Do you want to check out PRADAXA patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Jun 21, 2024
Pediatric Exclusivity (PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Market Authorisation Date: 19 October, 2010

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab

Dosage: CAPSULE;ORAL

How can I launch a generic of PRADAXA before it's patent expiration?
More Information on Dosage

PRADAXA family patents

16

United States

13

European Union

8

Japan

8

Norway

7

Germany

6

Korea, Republic of

6

New Zealand

6

China

5

Australia

5

Israel

5

Canada

5

Denmark

5

Spain

5

Cyprus

5

Portugal

5

Ukraine

5

Poland

5

Argentina

5

Slovenia

4

Ecuador

EA

4

EA

4

Croatia

4

Uruguay

4

Malaysia

4

Austria

4

Hong Kong

4

Mexico

4

South Africa

4

Brazil

4

Taiwan

3

Colombia

3

Luxembourg

3

Peru

3

ME

3

Singapore

YU

2

Yugoslavia

2

Chile

2

RS

2

Hungary

2

Lithuania

1

Netherlands

1

Tunisia

1

Morocco

1

Georgia

12. List of Spiriva drug patents

SPIRIVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070800 BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jan, 2022

(1 year, 4 months ago)

US7309707

(Pediatric)

 BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(1 year, 2 months ago)

US7642268

(Pediatric)

 BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(1 year, 2 months ago)

US6777423

(Pediatric)

 BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(1 year, 2 months ago)

US6908928

(Pediatric)

 BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(1 year, 2 months ago)

USRE38912

(Pediatric)

 BOEHRINGER INGELHEIM Process for preparing powder formulations
Apr, 2022

(1 year, 1 month ago)

US7070800

(Pediatric)

 BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jul, 2022

(10 months ago)

US8022082 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jan, 2026

(2 years from now)

US8022082

(Pediatric)

 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jul, 2026

(3 years from now)

US7694676 BOEHRINGER INGELHEIM Dry powder inhaler
Mar, 2027

(3 years from now)

US7694676

(Pediatric)

 BOEHRINGER INGELHEIM Dry powder inhaler
Sep, 2027

(4 years from now)

US9010323 BOEHRINGER INGELHEIM Inhaler and sieve for an inhaler
Apr, 2030

(6 years from now)

Do you want to check out SPIRIVA patents from before 2022?

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 30 January, 2004

Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inha...

Dosage: POWDER;INHALATION

How can I launch a generic of SPIRIVA before it's patent expiration?
More Information on Dosage

SPIRIVA family patents

17

United States

11

European Union

6

Japan

5

Australia

5

Canada

5

Spain

5

Poland

5

Germany

EA

4

EA

4

New Zealand

4

Denmark

4

ME

4

Portugal

4

Hong Kong

4

China

3

Israel

3

Croatia

3

Korea, Republic of

YU

3

Yugoslavia

3

Uruguay

3

Peru

3

Malaysia

3

Ukraine

3

Norway

3

Mexico

3

Slovenia

3

Argentina

3

Brazil

3

South Africa

3

Hungary

3

Taiwan

2

Ecuador

2

Egypt

2

Saudi Arabia

2

Austria

2

Slovakia

2

Estonia

2

Bulgaria

2

Czech Republic

AP

1

AP

1

Iceland

OA

1

OA

1

Costa Rica

1

Algeria

1

Cyprus

1

Morocco

1

Cuba

1

Georgia

1

Turkey

13. List of Spiriva Respimat drug patents

SPIRIVA RESPIMAT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7988001

(Pediatric)

 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Feb, 2022

(1 year, 3 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 2 months from now)

US7284474

(Pediatric)

 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(1 year, 8 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 11 months from now)

US7896264

(Pediatric)

 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(2 years from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7396341

(Pediatric)

 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(3 years from now)

US9027967

(Pediatric)

 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Oct, 2027

(4 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US7837235

(Pediatric)

 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

US8733341

(Pediatric)

 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Apr, 2031

(7 years from now)

Do you want to check out SPIRIVA RESPIMAT patents from before 2022?

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

SPIRIVA RESPIMAT family patents

12

European Union

9

Germany

9

United States

6

Japan

5

Canada

5

Spain

4

Australia

4

Denmark

4

Austria

3

Colombia

3

Korea, Republic of

3

Cyprus

3

Portugal

3

Poland

3

Slovenia

3

Mexico

3

Brazil

3

China

3

South Africa

2

Ecuador

EA

2

EA

2

Croatia

2

New Zealand

2

Uruguay

2

Peru

2

Ukraine

2

Norway

2

Hong Kong

2

Argentina

2

Taiwan

1

Israel

1

Egypt

YU

1

Yugoslavia

1

Malaysia

1

ME

1

Russia

1

RS

14. List of Stiolto Respimat drug patents

STIOLTO RESPIMAT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(5 months from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(6 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 11 months from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months from now)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 2 months from now)

US7284474

(Pediatric)

 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(1 year, 8 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 11 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 11 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7396341

(Pediatric)

 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US7837235

(Pediatric)

 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(5 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Do you want to check out STIOLTO RESPIMAT patents from before 2022?

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 21 May, 2015

Treatment: Treatment of copd; Treatment of respiratory complaints

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STIOLTO RESPIMAT family patents

20

United States

17

European Union

12

Germany

10

China

8

Japan

7

Canada

7

Spain

6

Australia

6

Denmark

5

Korea, Republic of

5

Austria

5

Cyprus

5

Portugal

5

Poland

5

Slovenia

5

Mexico

5

Brazil

5

South Africa

4

Colombia

4

New Zealand

4

Norway

4

Argentina

3

Ecuador

EA

3

EA

3

Israel

3

Croatia

3

Peru

3

Ukraine

3

Taiwan

YU

2

Yugoslavia

2

Uruguay

2

Malaysia

2

ME

2

Russia

2

Hong Kong

1

Luxembourg

1

Egypt

1

Netherlands

1

RS

1

Hungary

1

Lithuania

15. List of Striverdi Respimat drug patents

STRIVERDI RESPIMAT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(5 months from now)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(6 months from now)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 11 months from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months from now)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months from now)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(1 year, 2 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 11 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 11 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Do you want to check out STRIVERDI RESPIMAT patents from before 2022?

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STRIVERDI RESPIMAT family patents

20

United States

17

European Union

12

Germany

10

China

8

Japan

7

Canada

7

Spain

6

Australia

6

Denmark

5

Korea, Republic of

5

Austria

5

Cyprus

5

Portugal

5

Poland

5

Slovenia

5

Mexico

5

Brazil

5

South Africa

4

Colombia

4

New Zealand

4

Norway

4

Argentina

3

Ecuador

EA

3

EA

3

Israel

3

Croatia

3

Peru

3

Ukraine

3

Taiwan

YU

2

Yugoslavia

2

Uruguay

2

Malaysia

2

ME

2

Russia

2

Hong Kong

1

Luxembourg

1

Egypt

1

Netherlands

1

RS

1

Hungary

1

Lithuania

16. List of Synjardy drug patents

SYNJARDY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(3 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Sep, 2030

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

Do you want to check out SYNJARDY patents from before 2022?

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's patent expiration?
More Information on Dosage

SYNJARDY family patents

34

United States

22

European Union

13

Japan

13

China

9

Canada

8

Israel

8

Korea, Republic of

7

Hong Kong

7

Argentina

6

Australia

6

Spain

6

Peru

EA

5

EA

5

Croatia

5

New Zealand

5

Denmark

5

Portugal

5

Poland

5

Germany

5

Mexico

5

RS

4

Uruguay

4

Chile

4

Cyprus

4

Norway

4

Slovenia

4

Taiwan

3

Austria

3

ME

3

Ukraine

3

Philippines

3

Brazil

3

Hungary

3

Lithuania

2

Ecuador

2

Malaysia

2

South Africa

AP

1

AP

1

Luxembourg

1

India

1

Tunisia

1

Singapore

1

Morocco

1

Finland

1

Turkey

17. List of Synjardy Xr drug patents

SYNJARDY XR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(3 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(8 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(10 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Do you want to check out SYNJARDY XR patents from before 2022?

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer c...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

SYNJARDY XR family patents

37

United States

22

European Union

14

Japan

12

China

9

Canada

8

Korea, Republic of

7

Israel

7

Argentina

6

Hong Kong

5

Australia

EA

5

EA

5

New Zealand

5

Spain

5

Peru

5

Germany

5

Mexico

4

Croatia

4

Denmark

4

Uruguay

4

Chile

4

Portugal

4

Poland

4

Norway

4

RS

3

Austria

3

Cyprus

3

Philippines

3

Slovenia

3

Brazil

3

Taiwan

2

Malaysia

2

ME

2

Singapore

2

Ukraine

2

South Africa

2

Hungary

2

Lithuania

1

Ecuador

1

Luxembourg

1

Finland

1

Turkey

18. List of Tradjenta drug patents

TRADJENTA's oppositions filed in EPO
TRADJENTA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(2 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(2 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(7 years from now)

Do you want to check out TRADJENTA patents from before 2022?
Exclusivity Exclusivity Expiration
M (M) Mar 30, 2023

Drugs and Companies using LINAGLIPTIN ingredient

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea; Method of treating type 2 diabetes mellitus by administering a dipepti...

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's patent expiration?
More Information on Dosage

TRADJENTA family patents

45

United States

34

Japan

34

European Union

27

China

24

Korea, Republic of

19

New Zealand

EA

13

EA

12

Taiwan

10

Hong Kong

10

Mexico

9

Australia

9

Canada

9

Malaysia

9

Argentina

9

Brazil

8

Spain

8

Peru

8

Poland

7

Denmark

7

Chile

7

Norway

7

Germany

6

Croatia

6

Portugal

6

Ukraine

5

Ecuador